Literature DB >> 17698262

Plasmid DNA and viral vector-based vaccines for the treatment of cancer.

Richard J Anderson1, Joerg Schneider.   

Abstract

Plasmid DNA and viral vector-based cancer vaccines have many inherent features that make them promising cancer vaccine candidates. This review focuses on the use of plasmid DNA and viral vector vaccines to deliver tumour-specific antigens to induce a tumour-specific immune response. Examples of different antigen delivery systems that have been tested in recent clinical trials are summarised and advantages and disadvantages of a number of delivery systems and approaches are discussed. Finally, an outlook on how plasmid DNA and viral vectors might be developed further as cancer vaccines is provided.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17698262     DOI： 10.1016/j.vaccine.2007.05.030

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  19 in total

1.  Blockade of programmed death-1 pathway rescues the effector function of tumor-infiltrating T cells and enhances the antitumor efficacy of lentivector immunization.

Authors:  Qifeng Zhou; Haiyan Xiao; Yanjun Liu; Yibing Peng; Yuan Hong; Hideo Yagita; Phillip Chandler; David H Munn; Andrew Mellor; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2010-10-06       Impact factor: 5.422

2.  Anti-tumor effect of the alphavirus-based virus-like particle vector expressing prostate-specific antigen in a HLA-DR transgenic mouse model of prostate cancer.

Authors:  V Riabov; I Tretyakova; R B Alexander; P Pushko; E N Klyushnenkova
Journal:  Vaccine       Date:  2015-08-28       Impact factor: 3.641

Review 3.  Poly-N-acetyl glucosamine gel matrix as a non-viral delivery vector for DNA-based vaccination.

Authors:  Mohamed L Salem; Marina Demcheva; William E Gillanders; David J Cole; John N Vournakis
Journal:  Anticancer Res       Date:  2010-10       Impact factor: 2.480

Review 4.  Micro- and nanoparticulates for DNA vaccine delivery.

Authors:  Eric Farris; Deborah M Brown; Amanda E Ramer-Tait; Angela K Pannier
Journal:  Exp Biol Med (Maywood)       Date:  2016-04-04

5.  Lentivector prime and vaccinia virus vector boost generate high-quality CD8 memory T cells and prevent autochthonous mouse melanoma.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Yanjun Liu; Z Sheng Guo; David L Bartlett; Ning Fu; Yukai He
Journal:  J Immunol       Date:  2011-07-11       Impact factor: 5.422

6.  Immunoglobulin Fc fragment tagging allows strong activation of endogenous CD4 T cells to reshape the tumor milieu and enhance the antitumor effect of lentivector immunization.

Authors:  Yuan Hong; Yibing Peng; Haiyan Xiao; Michael Mi; David Munn; Yukai He
Journal:  J Immunol       Date:  2012-04-13       Impact factor: 5.422

7.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01

8.  Local administration of TLR ligands rescues the function of tumor-infiltrating CD8 T cells and enhances the antitumor effect of lentivector immunization.

Authors:  Haiyan Xiao; Yibing Peng; Yuan Hong; Lei Huang; Z Sheng Guo; David L Bartlett; Ning Fu; David H Munn; Andrew Mellor; Yukai He
Journal:  J Immunol       Date:  2013-04-22       Impact factor: 5.422

Review 9.  DNA vaccines: developing new strategies against cancer.

Authors:  Daniela Fioretti; Sandra Iurescia; Vito Michele Fazio; Monica Rinaldi
Journal:  J Biomed Biotechnol       Date:  2010-03-28

10.  Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.

Authors:  Janet L Brandsma; Mark Shlyankevich; Yuhua Su; Daniel Zelterman; John K Rose; Linda Buonocore
Journal:  Vaccine       Date:  2009-07-15       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.